收费全文 | 3061篇 |
免费 | 214篇 |
国内免费 | 14篇 |
耳鼻咽喉 | 23篇 |
儿科学 | 142篇 |
妇产科学 | 108篇 |
基础医学 | 424篇 |
口腔科学 | 46篇 |
临床医学 | 290篇 |
内科学 | 633篇 |
皮肤病学 | 88篇 |
神经病学 | 344篇 |
特种医学 | 70篇 |
外科学 | 339篇 |
综合类 | 31篇 |
一般理论 | 7篇 |
预防医学 | 258篇 |
眼科学 | 58篇 |
药学 | 174篇 |
中国医学 | 16篇 |
肿瘤学 | 238篇 |
2024年 | 7篇 |
2023年 | 50篇 |
2022年 | 97篇 |
2021年 | 162篇 |
2020年 | 100篇 |
2019年 | 127篇 |
2018年 | 139篇 |
2017年 | 108篇 |
2016年 | 110篇 |
2015年 | 112篇 |
2014年 | 142篇 |
2013年 | 153篇 |
2012年 | 272篇 |
2011年 | 301篇 |
2010年 | 152篇 |
2009年 | 123篇 |
2008年 | 188篇 |
2007年 | 166篇 |
2006年 | 152篇 |
2005年 | 146篇 |
2004年 | 117篇 |
2003年 | 94篇 |
2002年 | 90篇 |
2001年 | 19篇 |
2000年 | 11篇 |
1999年 | 10篇 |
1998年 | 12篇 |
1997年 | 10篇 |
1996年 | 6篇 |
1995年 | 8篇 |
1994年 | 8篇 |
1993年 | 8篇 |
1992年 | 13篇 |
1991年 | 4篇 |
1990年 | 10篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 4篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1978年 | 2篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1974年 | 6篇 |
1973年 | 2篇 |
1970年 | 2篇 |
1969年 | 2篇 |
Introduction
Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.Method
A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.Results
The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case.Discussion
The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. 相似文献Methods: A retrospective cohort study of patients with IU who had a minimal follow-up of one year.
Results: 96 patients (174 eyes, 70% females) were included with a mean age at presentation of 30 years. Children constituted 38% of all patients. Mean follow- up was 64.9 months. Pars planitis was the most common form followed by sarcoidosis and multiple sclerosis. Cystoid macular edema (CME), cataract, epiretinal membrane and posterior synechiae were the most prevalent complications. Posterior synechiae, band keratopathy, cataract and papillitis at presentation were associated with worse presenting visual acuity (VA). Of the late-onset complications, glaucoma/ocular hypertension (OHT) was the most significantly associated with worse long-term VA. Most sight-threatening complications (namely CME and glaucoma) were diagnosed at presentation while late complications predominantly affected the posterior segment and included among others peripheral retinal elevations, vasoproliferative tumors, and vitreous hemorrhage. Median LogMAR VA improved at short-term and long-term follow-up, from 0.2 to 0.1 (p<0.001). Subgroup analysis revealed significant VA improvement for eyes with all the different complications except for eyes with glaucoma/OHT.
Conclusion: IU is a chronic low-grade uveitis that may be associated with protean early and late complications of the anterior or posterior segments or both. Optimal treatment regimens are imperative for the strict control of inflammation and proper management of complications thus allowing a favorable long-term prognosis. 相似文献